Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access February 13, 2014

Differences on the prevalence of cervical HPV between Lithuania and Belarus

  • Zivile Gudleviciene EMAIL logo , Daiva Kanopiene , Janina Didziapetriene , Raisa Smolyakova , Ekaterina Gutkovskaya , Alexander Zhukovec and Galina Kostevich
From the journal Open Medicine


In some countries the cervical cancer incidence and mortality rates are much higher compared to the European average. The differences of HPV and its type prevalence between countries and regions influence cervical cancer incidence and mortality. Regarding the differences in cervical cancer incidence and mortality in Lithuania and Belarus, the aim of this study was to describe HPV infection level and HPVs type distribution among two study groups of patients with moderate or severe cervical intraepithelial neoplasia (CIN2-3) and cervical cancer. Our data shows that 74.2% [95% CI: 63.64÷84.76] of Lithuanian patients with cervical cancer and 85.6% [95% CI: 85.53÷92.85] of the study group with CIN2-3 were HPV positive, while in the study groups of Belarusian patients HPV infection was detected in 92.6% [95% CI, 74.25÷98.71] and 65.4% [95% CI, 44.36÷82.06] cases respectively. HPV 16 was the most prevalent type in Lithuanian as well as in Belarusian patients of the study groups. HPV 18 in Lithuanian patients of the study group with cervical cancer was identified in 10.2% [95% CI: 1.73÷18.67] and in the study group with CIN2-3 — in 2.6% [95% CI: 0.95÷6.15] of cases. HPV 18 was not detected in Belarusian patients of both groups.

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available from:, accessed on day/month/year Search in Google Scholar

[2] Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nati Cancer Inst. 2006;98(5):303–315 in Google Scholar PubMed

[3] Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244–265 in Google Scholar PubMed PubMed Central

[4] Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527 in Google Scholar PubMed

[5] Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):1–10 in Google Scholar PubMed

[6] Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007;107:S2–S5 in Google Scholar PubMed

[7] Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117(2):S5–S10 in Google Scholar PubMed

[8] Anttila A, Ronco G: Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009;45(15):2685–2708 in Google Scholar PubMed

[9] Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition-Summary Document. Ann Oncol 2010;21(3):448–458 in Google Scholar PubMed PubMed Central

[10] WHO/Europe, European HFA Database, January 2012 Search in Google Scholar

[11] Popendikyte V, Gulbinovic I, Paulauskiene V, Paulauskas D. High risk human papilloma virus detection and genotyping by multiplex PCR. Lietuvos akuserija ir ginekologija (Lithuanian Obstetrics and Gynecology) 2000;11:348–352 Search in Google Scholar

[12] Cancer in Lithuania 2009. Institute of Oncology, Vilnius University. Cancer registry data, 2011 (available in Search in Google Scholar

[13] Gudlevicienė Z, Didziapetriene J, Ramael M, Uleckiene S, Valuckas KP: Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol Oncol 2006;102(3):530–533 in Google Scholar PubMed

[14] Gudlevicienė Z, Didziapetriene J, Suziedelis K, Lapkauskaite L. Investigation of human papillomavisur its types and variants. Medicina (Lithuania) 2005;41(11):910–915 Search in Google Scholar

[15] Istomin YP, Lapzevich TP, Chalau VN, Shliakhtsin SV, Trukhachova TV. Photodynamic therapy of cervical intraepithelial neoplasia grades II and III with Photolon. Photodiagnosis Photodyn Ther 2010;7(3):144–151 in Google Scholar PubMed

[16] Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB, Syrjänen SM; NIS Study Group. Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 2007;79(6):771–781 in Google Scholar PubMed

[17] Wężowska M, Giedrys-Kalemba S, Szymaniak L, Borowiec-Chłopek Ż, Konstanty-Kurkiewicz V, Menkiszak J. Risk factors for cervical cancer among young women. Central European Journal of Medicine. Central European Journal of Medicine 2012, DOI: 10.2478/s11536-012-0063-3 10.2478/s11536-012-0063-3Search in Google Scholar

[18] IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 90, Human Papillomaviruses, IARC Monographs 2007 Search in Google Scholar

Published Online: 2014-2-13
Published in Print: 2014-4-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 6.12.2023 from
Scroll to top button